+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years - 75Years
All Genders
ID07734311

Phase III Study of Weekly Ecnoglutide Injection Versus Placebo for Obese Adults with Knee Osteoarthritis Evaluating Pain and Weight Changes

Led by Hangzhou Sciwind Biosciences Co., Ltd. · Updated on 2026-08-31

360

Participants Needed

1

Research Sites

4 weeks

Total Duration

AI-Summary

What This Trial Is About

This research aims to evaluate the effectiveness and safety of ecnoglutide injections compared to placebo in adults with obesity and knee osteoarthritis KOA. It is a Phase III randomized, double-blind, placebo-controlled study focusing on obese participants with KOA to understand how ecnoglutide may impact pain and weight. Participants are randomly assigned to receive either once-weekly subcutaneous ecnoglutide injections or placebo. The study includes a dose-escalation phase and lasts up to 68 weeks of treatment, followed by a 5-week follow-up, totaling 73 weeks for each participant. During the study, participants will have scheduled visits for assessments including pain measurement using the Western Ontario and McMaster Universities Osteoarthritis Index WOMAC, body weight tracking, physical function tests, blood tests, and questionnaires about quality of life and mental health. Safety will be monitored throughout, and researchers will evaluate changes from baseline to week 68 and week 73.

CONDITIONS

Brief Title

A Study of Econoglutide Injection in Obese Participants With Knee Osteoarthritis (KOA)

Research Team

Y

Yao Li

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here